Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Near-infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts in Patient-Derived Xenografts using a Humanized anti-Fibroblast Activation Protein Antibody.
Kobayashi T, Noma K, Nishimura S, Kato T, Nishiwaki N, Ohara T, Kunitomo T, Kawasaki K, Akai M, Komoto S, Kashima H, Kikuchi S, Tazawa H, Shirakawa Y, Choyke PL, Kobayashi H, Fujiwara T. Kobayashi T, et al. Among authors: kunitomo t. Mol Cancer Ther. 2024 Apr 18. doi: 10.1158/1535-7163.MCT-23-0527. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38638034
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody.
Nishiwaki N, Noma K, Ohara T, Kunitomo T, Kawasaki K, Akai M, Kobayashi T, Narusaka T, Kashima H, Sato H, Komoto S, Kato T, Maeda N, Kikuchi S, Tanabe S, Tazawa H, Shirakawa Y, Fujiwara T. Nishiwaki N, et al. Among authors: kunitomo t. Cancer Immunol Immunother. 2023 Jul;72(7):2029-2044. doi: 10.1007/s00262-023-03378-7. Epub 2023 Feb 10. Cancer Immunol Immunother. 2023. PMID: 36764954 Free PMC article.
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity.
Akai M, Noma K, Kato T, Nishimura S, Matsumoto H, Kawasaki K, Kunitomo T, Kobayashi T, Nishiwaki N, Kashima H, Kikuchi S, Ohara T, Tazawa H, Choyke PL, Kobayashi H, Fujiwara T. Akai M, et al. Among authors: kunitomo t. Br J Cancer. 2024 Jun;130(10):1647-1658. doi: 10.1038/s41416-024-02639-1. Epub 2024 Mar 30. Br J Cancer. 2024. PMID: 38555315 Free PMC article.
PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K, Noma K, Kato T, Ohara T, Tanabe S, Takeda Y, Matsumoto H, Nishimura S, Kunitomo T, Akai M, Kobayashi T, Nishiwaki N, Kashima H, Maeda N, Kikuchi S, Tazawa H, Shirakawa Y, Fujiwara T. Kawasaki K, et al. Among authors: kunitomo t. Cancer Immunol Immunother. 2023 Nov;72(11):3787-3802. doi: 10.1007/s00262-023-03531-2. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668710 Free PMC article.
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N, Noma K, Kunitomo T, Hashimoto M, Maeda N, Tanabe S, Sakurama K, Shirakawa Y, Fujiwara T. Nishiwaki N, et al. Among authors: kunitomo t. Esophagus. 2022 Oct;19(4):626-638. doi: 10.1007/s10388-022-00934-5. Epub 2022 Jul 6. Esophagus. 2022. PMID: 35792947
66 results